Granisetron (tablet): Difference between revisions
Shanshan Cen (talk | contribs) No edit summary |
Shanshan Cen (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage01 | {{DrugProjectFormSinglePage01 | ||
|authorTag={{SC}} | |authorTag={{SC}} | ||
|genericName=Granisetron | |||
|aOrAn=an | |||
|drugClass=antiemetic | |||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Granisetron (tablet) in adult patients. | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Granisetron (tablet) in adult patients. | ||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Granisetron (tablet) in adult patients. | |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Granisetron (tablet) in adult patients. |
Revision as of 19:37, 14 May 2015
For patient information regarding Granisetron, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Granisetron (tablet) is an antiemetic that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
{{{fdaLIADAdult}}}
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Granisetron (tablet) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Granisetron (tablet) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
{{{fdaLIADPed}}}
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Granisetron (tablet) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Granisetron (tablet) in pediatric patients.
Contraindications
{{{contraindications}}}
Warnings
{{{warnings}}}
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trials Experience of Granisetron (tablet) in the drug label.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Granisetron (tablet) in the drug label.
Drug Interactions
{{{drugInteractions}}}
Use in Specific Populations
Pregnancy
{{{useInPregnancyFDA}}}
Labor and Delivery
There is no FDA guidance on the use of Granisetron (tablet) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Granisetron (tablet) with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Granisetron (tablet) with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Granisetron (tablet) with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Granisetron (tablet) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Granisetron (tablet) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Granisetron (tablet) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Granisetron (tablet) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Granisetron (tablet) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance on the use of Granisetron (tablet) in patients who are immunocompromised.
Administration and Monitoring
Administration
{{{administration}}}
Monitoring
There is limited information regarding Monitoring of Granisetron (tablet) in the drug label.
Overdosage
{{{overdose}}}
Pharmacology
{{{drugBox}}}
Mechanism of Action
{{{mechAction}}}
Structure
{{{structure}}}
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Granisetron (tablet) in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Granisetron (tablet) in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Granisetron (tablet) in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Granisetron (tablet) in the drug label.
How Supplied
{{{howSupplied}}}
Images
Package and Label Display Panel
{{{packLabel}}}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Granisetron (tablet) in the drug label.
Precautions with Alcohol
Alcohol-Granisetron (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
®
Look-Alike Drug Names
A® — B®
Drug Shortage Status
References
The contents of this FDA label are provided by the National Library of Medicine.